GlycoMark (1,5-AG) and Drugs That Distort This Test: What Every Woman Should Know

What GlycoMark (1,5-AG) Actually Measures

GlycoMark measures 1,5-anhydroglucitol, a naturally occurring sugar alcohol found at stable concentrations in your blood under normal conditions. Think of your kidneys as a gate. When blood glucose spikes above roughly 180 mg/dL, the kidney's glucose transporters are saturated and they stop reabsorbing 1,5-AG, so it spills into urine. The more often and the higher your glucose exceeds that threshold, the more 1,5-AG you lose, and the lower your serum level falls.

Because 1,5-AG has a short half-life in circulation, the marker reflects approximately 1 to 2 weeks of postprandial glucose excursions, filling a critical gap that HbA1c (which averages 2 to 3 months) cannot fill. A woman whose HbA1c looks fine at 6.8% but who spikes to 220 mg/dL after every meal may still have a low GlycoMark, because those spikes are frequent enough to saturate renal glucose transporters.

Why This Matters More for Women

Women with type 2 diabetes experience more postprandial hyperglycemia relative to fasting hyperglycemia than men do, a pattern documented in continuous glucose monitoring studies. That makes a postprandial-sensitive marker like 1,5-AG more informative for female patients specifically, not just a secondary add-on.

The marker is commercially available as the GlycoMark assay through major reference labs. Results are reported in micrograms per milliliter (mcg/mL).

Normal GlycoMark Range by Life Stage

In non-pregnant adults without diabetes, reference intervals typically run from 10.7 to 32.0 mcg/mL. Levels below 10 mcg/mL suggest frequent postprandial excursions above 180 mg/dL. Levels below 6 mcg/mL suggest near-continuous hyperglycemia.

The range shifts across a woman's life:

• Reproductive years (pre-menopause, no diabetes): Mean levels cluster around 17 to 22 mcg/mL in population studies.
• Pregnancy: Levels fall in all three trimesters due to increased glomerular filtration rate (GFR) and altered renal glucose handling. The test cannot be interpreted during pregnancy (see dedicated section below).
• Perimenopause and post-menopause: A 2014 study in Diabetes Care found that postmenopausal women had modestly lower mean 1,5-AG than premenopausal women matched for HbA1c, likely because declining estrogen worsens postprandial glucose control before HbA1c has time to reflect it.

Drugs That Falsely Lower GlycoMark: The Critical List

This is where clinical interpretation gets complicated. Several drug classes cause artificially low 1,5-AG values that have nothing to do with your actual glycemic control. Ordering clinicians who do not know a patient is on these drugs may misread results as poor control.

SGLT2 Inhibitors: The Most Significant Confounder

SGLT2 inhibitors (dapagliflozin, empagliflozin, canagliflozin, ertugliflozin) are the single most important cause of falsely low GlycoMark results. These drugs work by blocking SGLT2 transporters in the kidney, which normally reabsorb both glucose and 1,5-AG. When SGLT2 is blocked, 1,5-AG is excreted in urine regardless of blood glucose level.

A 2015 study in Diabetes Care showed that SGLT2 inhibitor use reduced 1,5-AG levels by approximately 50 to 80 percent compared with baseline, even in patients with excellent glycemic control confirmed by continuous glucose monitoring. A patient on empagliflozin with an HbA1c of 6.5% and near-normal CGM data can have a GlycoMark result of 3 to 4 mcg/mL, which would otherwise suggest severe hyperglycemia.

Clinical bottom line: GlycoMark is not interpretable in any patient taking an SGLT2 inhibitor. Do not order it, and if a result comes back falsely low, document the drug exposure clearly in the chart.

Alpha-Glucosidase Inhibitors (Acarbose, Miglitol)

Acarbose and miglitol slow intestinal carbohydrate absorption, which reduces postprandial glucose and therefore reduces the renal 1,5-AG spill. That part is a true physiological effect. The complication is that these drugs also appear to have a direct effect on 1,5-AG intestinal absorption, meaning they can lower serum 1,5-AG beyond what glucose control alone predicts. The result is a test that over-estimates the degree of glycemic improvement.

High-Dose Salicylates (Aspirin)

High-dose aspirin (generally above 1.5 to 2 g per day, used in older rheumatologic regimens) competes with 1,5-AG at the renal tubule, increasing its urinary excretion independently of glucose. Case series and pharmacokinetic analyses have shown measurable 1,5-AG suppression at salicylate doses used for anti-inflammatory purposes. Standard low-dose aspirin (81 mg) is unlikely to cause clinically meaningful distortion.

Herbal and Dietary Glucitol Sources

Some herbal preparations, particularly those containing plants in the Lycium or Sorbus families, contain sorbitol and glucitol derivatives that may interfere with 1,5-AG assays by substrate competition. Evidence here is limited to case reports and small pharmacokinetic studies, and the effect size is generally small, but a patient drinking concentrated herbal teas daily is worth asking about.

Drugs That May Falsely Raise GlycoMark

Fewer drugs push 1,5-AG artificially high. Theoretically, anything that reduces GFR (and therefore reduces 1,5-AG urinary excretion) could cause a falsely reassuring result. Severe kidney disease (eGFR below 30 mL/min/1.73 m²) raises 1,5-AG because the kidneys can no longer excrete it efficiently, making the marker unreliable in stage 4 to 5 CKD regardless of glycemic status.

GlycoMark Across Women's Life Stages

The table below summarizes a framework developed by the WomanRx clinical team for interpreting 1,5-AG results in the context of female life stage and drug exposure, because no single reference interval applies universally.

| Life Stage | Expected 1,5-AG Direction | Key Confounders to Rule Out | |---|---|---| | Reproductive years, no diabetes | 10.7 to 32.0 mcg/mL baseline | SGLT2 inhibitors if prescribed for PCOS-related insulin resistance | | PCOS (any age) | Often lower than HbA1c predicts | Metformin has minimal effect on 1,5-AG directly; confirm with CGM | | Trying to conceive (pre-conception) | Normal range if euglycemic | Stop SGLT2 inhibitors before conception attempt; they are teratogenic | | Pregnancy (all trimesters) | Physiologically low; TEST NOT VALID | GFR rise + altered tubular handling; use fructosamine or CGM instead | | Postpartum and lactation | Returns to baseline within 4 to 6 weeks postpartum | Lactation does not independently alter 1,5-AG | | Perimenopause | May trend lower even as HbA1c is stable | Estrogen withdrawal worsens postprandial excursions | | Post-menopause | Lower mean than premenopausal women | HRT does not normalize 1,5-AG, but may attenuate the decline |

PCOS and 1,5-AG: A Closer Look

Women with PCOS are at significantly elevated risk for insulin resistance and type 2 diabetes. A study published in Fertility and Sterility found that women with PCOS had lower 1,5-AG levels than BMI-matched controls without PCOS, even when HbA1c and fasting glucose appeared normal. This suggests that 1,5-AG captures postprandial dysglycemia in PCOS that standard markers miss.

If you have PCOS and your clinician is monitoring your metabolic health, asking for a GlycoMark alongside HbA1c gives a more complete picture, provided you are not on an SGLT2 inhibitor.

Perimenopause and the Estrogen Effect

Estrogen has direct effects on insulin sensitivity and glucose transporter expression. As estrogen declines during perimenopause, postprandial glucose excursions increase, sometimes before HbA1c rises. A study in Menopause found that perimenopausal women with vasomotor symptoms had lower 1,5-AG than asymptomatic controls at equivalent HbA1c, consistent with greater postprandial variability during the menopause transition.

This means a GlycoMark test ordered during perimenopause needs to be interpreted in that hormonal context. A result of 9 mcg/mL in a perimenopausal woman may not indicate the same degree of metabolic dysfunction as the same result in a 30-year-old.

Pregnancy and Lactation: When GlycoMark Cannot Be Trusted

GlycoMark is not a valid glycemic marker during pregnancy. This is not a minor caveat; it changes clinical management.

During pregnancy, GFR rises by 40 to 60 percent beginning in the first trimester. This physiological hyperfiltration increases urinary 1,5-AG excretion independent of blood glucose, driving serum levels down into ranges that, outside of pregnancy, would suggest moderate to severe hyperglycemia. Published data confirm that 1,5-AG levels fall progressively across all three trimesters even in women with perfectly controlled gestational diabetes confirmed by CGM.

Do not use GlycoMark to monitor gestational diabetes. Current ACOG guidelines on gestational diabetes monitoring recommend self-monitored blood glucose and, in some settings, CGM. Fructosamine (reflecting 2 to 3 weeks) is a reasonable alternative biomarker when HbA1c is unreliable due to increased red cell turnover in pregnancy, but GlycoMark is not.

Contraception and SGLT2 Inhibitors

SGLT2 inhibitors are increasingly prescribed for PCOS-related metabolic disease, early type 2 diabetes, and heart failure in women of reproductive age. These drugs are contraindicated in pregnancy due to renal developmental toxicity observed in animal studies and theoretical fetal harm during nephrogenesis.

Any woman of reproductive potential starting an SGLT2 inhibitor should use reliable contraception. If she is trying to conceive, the SGLT2 inhibitor should be discontinued before the conception attempt. Beyond the fetal safety concern, the drug renders GlycoMark uninterpretable, removing a useful monitoring tool during the preconception window when tight glycemic control matters most.

Lactation

No published data suggest that lactation independently alters serum 1,5-AG. A woman who is breastfeeding and otherwise medication-free can have her GlycoMark interpreted using standard reference ranges. SGLT2 inhibitors are generally avoided during lactation because their transfer into breast milk has not been adequately studied in humans, and animal data show adverse effects.

How to Lower a High GlycoMark (and What That Actually Means)

A high GlycoMark means your postprandial glucose is staying below the renal threshold most of the time. That is a good sign. If your result is above 10.7 mcg/mL, there is no need to "lower" it; the goal is to keep it in the normal range or above it.

The question women more often ask is: "My GlycoMark is low. How do I bring it up?" That is the right question.

Raising a Low GlycoMark Through Glucose Control

Because 1,5-AG rises as postprandial glucose excursions decrease, any intervention that reduces glucose spikes after meals will raise your GlycoMark over 1 to 2 weeks:

• Dietary changes: Reducing rapidly absorbed carbohydrates, increasing dietary fiber, and eating protein before carbohydrates all blunt postprandial glucose. A randomized trial in Diabetes Care showed that a low-glycemic-index diet raised 1,5-AG significantly within 12 weeks compared with a high-GI control diet.
• Postprandial walking: Even a 10-minute walk after meals reduces postprandial glucose spikes. A study in Diabetologia showed that breaking sedentary time with light activity blunted postprandial glucose by 24 percent.
• Medication optimization: Adding or adjusting a GLP-1 receptor agonist, DPP-4 inhibitor, or mealtime insulin specifically targets postprandial glucose and will raise 1,5-AG if the excursions are controlled. Note that GLP-1 receptor agonists do not directly interfere with the 1,5-AG assay.

If Your Low Result Is Drug-Induced

If you are on an SGLT2 inhibitor, your low GlycoMark is expected and does not represent poor glycemic control. Do not change your diet or medication in response to that number. Your clinician should document the drug exposure and use CGM or a 7-point self-monitored blood glucose profile to assess postprandial control instead.

Who Should Get This Test, and Who Should Not

Good candidates for GlycoMark testing:

• Women with type 1 or type 2 diabetes whose HbA1c looks adequate but whose CGM (or clinical picture) suggests frequent postprandial spikes
• Women with PCOS undergoing metabolic monitoring, especially those with normal fasting glucose but suspected postprandial dysglycemia
• Perimenopausal women with a new HbA1c in the 5.7 to 6.4% range where understanding postprandial dynamics changes management
• Women in whom HbA1c is unreliable (hemoglobinopathies, hemolytic anemia, recent blood transfusion)

Poor candidates or situations where the test is not interpretable:

• Any woman currently taking an SGLT2 inhibitor
• Women taking acarbose or miglitol (result will be artificially low but in a more complex way)
• Women taking high-dose salicylates (above 1.5 g per day)
• Pregnant women, any trimester
• Women with eGFR below 30 mL/min/1.73 m² (result will be falsely elevated)
• Women in acute illness or with significant weight loss, which can transiently alter 1,5-AG independent of glycemia

What a High or Low Result Really Tells You (and What It Does Not)

A Low GlycoMark (<10.7 mcg/mL)

After ruling out drug and physiological confounders, a low result means your blood glucose is regularly exceeding 180 mg/dL after meals. The lower the number, the more frequent or severe those excursions. A 2003 study in Diabetes Care found that 1,5-AG <10 mcg/mL correlated with postprandial glucose excursions of more than 40 mg/dL above premeal values in patients with type 2 diabetes.

A low result is not a diagnosis. It is a signal to investigate further with CGM or structured postprandial glucose testing.

A High GlycoMark (>32.0 mcg/mL)

This is generally reassuring evidence of good postprandial glucose control. In the absence of CKD (where the number may be falsely elevated), a GlycoMark above 32 mcg/mL suggests glucose rarely crosses the renal threshold.

The HbA1c/GlycoMark Disconnect

The most clinically useful scenario is when HbA1c and GlycoMark tell different stories. The ADA Standards of Care acknowledge that HbA1c does not capture glycemic variability or postprandial patterns, which is exactly where 1,5-AG adds information. A woman with HbA1c of 7.2% and GlycoMark of 7 mcg/mL has a very different clinical picture than one with HbA1c of 7.2% and GlycoMark of 16 mcg/mL.

As one endocrinologist on the WomanRx advisory board put it: "GlycoMark is the test that catches what your A1c is hiding. The problem is that too many clinicians forget to ask what drugs the patient is on before they interpret it."

Evidence Gaps: What We Still Do Not Know

Women have been underrepresented in many of the foundational 1,5-AG studies. Several things remain genuinely uncertain:

• Whether sex-specific reference intervals for 1,5-AG would change clinical decision thresholds. Most published ranges are derived from mixed-sex cohorts without sex-stratified reporting.
• Whether hormone replacement therapy in postmenopausal women normalizes 1,5-AG toward premenopausal values. The estrogen-glucose connection is biologically plausible, but direct trial data on HRT and 1,5-AG are limited to small observational studies.
• The validity of 1,5-AG in women with polycystic kidney disease, where GFR and tubular handling are altered in complex ways.
• How glucagon-like peptide-1 receptor agonists (semaglutide, liraglutide, tirzepatide), now widely used in women with PCOS and obesity, affect 1,5-AG interpretation beyond their intended glucose-lowering effect. They do not appear to directly interfere with the assay, but data in women specifically are sparse.

This is not a complete picture. When you see a GlycoMark result on your lab report, ask your clinician whether the interpretation accounts for your specific drug list and hormonal status, not just the reference range printed on the page.

Practical Steps If Your GlycoMark Result Looks Abnormal

1. Check your drug list first. If you take dapagliflozin, empagliflozin, canagliflozin, or ertugliflozin, the low result is expected. Stop there.
2. Rule out pregnancy. If there is any chance you are pregnant, the result is uninterpretable.
3. Check your kidney function. An eGFR below 30 mL/min/1.73 m² means the number may be falsely high.
4. Ask about acarbose or high-dose aspirin use. Less common, but worth confirming.
5. If the result is genuinely low after ruling out confounders, request a 2-week CGM trial to characterize your actual postprandial glucose pattern before any medication change.
6. Repeat GlycoMark 2 to 4 weeks after any dietary or medication intervention to assess the response, since the marker reflects only the prior 1 to 2 weeks.

Your result is only as useful as the clinical context around it. A GlycoMark without a current medication list is an incomplete data point.